A Pilot Study of Polysubstance Use Sequences across the Lifespan among Assiniboine and Sioux People Who Use Injection Drugs

Author:

Anastario MichaelORCID,Firemoon Paula,Rodriguez Ana Maria,Wade Carrie,Prokosch Christopher,Rink Elizabeth,Wagner EricORCID

Abstract

Compared with other racial/ethnic groups in the United States, American Indians/Alaska Natives have the highest rates of acute Hepatitis C Virus (HCV) infection, the highest HCV-related mortality, and one of the fastest climbing rates of drug overdose deaths involving stimulants. In this pilot study, a life history calendar was administered to Indigenous people who use injection drugs (IPWIDs) to understand sequences of polysubstance use across the lifespan. 40 IPWIDs completed a questionnaire and life history calendar. Social sequence analysis was used to examine patterns in sequential phenomena among substances reported over years of the lifespan. Most participants (55%) began injecting substances before the age of 21, 62.5% shared syringes with others, and 45% had ever been diagnosed with HCV. An appreciably large increase in the use of stimulants occurred between the year prior to and following injection initiation (33% to 82%). A three-cluster solution distinguished younger IPWIDs transitioning into polysubstance use involving stimulants and/or narcotic analgesics from adults using narcotic analgesics with stimulants over longer periods of time, and adults most focused on stimulant use over time. Findings from this pilot study contribute to an understanding of how methamphetamine injection plays a role in the HCV epidemic among IPWIDs.

Funder

National Institute On Minority Health and Health Disparities of the National Institutes of Health

Publisher

MDPI AG

Subject

Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health

Reference77 articles.

1. US Centers for Disease Control and Prevention (2022, May 19). Figure 3.6. Rates of Reported Acute Hepatitis C Virus Infection, by Race/Ethnicity—United States, 2004–2019. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Viral Hepatitis Surveillance, United States, Available online: https://www.cdc.gov/hepatitis/statistics/2019surveillance/Figure3.6.htm.

2. US Centers for Disease Control and Prevention (2022, May 19). Table 3.8. Number and Rates of Deaths with Hepatitis C Virus Infection Listed as a Cause of Death Among Residents, by Demographic Characteristics—United States, 2015–2019. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Viral Hepatitis Surveillance, United States, Available online: https://www.cdc.gov/hepatitis/statistics/2019surveillance/Table3.8.htm.

3. Roehler, D., Hoots, E., Olsen, M., Kariisa, N., Otoo Wilson, R., Rudd, D., Mustaquim, L., Xu, L., and Schieber, L. (2022, December 23). Annual Surveillance Report of Drug-Related Risks and Outcomes, United States. Centers for Disease Control and Prevention, Available online: https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf.

4. Centers for Disease Control and Prevention (2022, May 19). Age-Adjusted Rates of Drug Overdose Deaths Involving Prescription Opioids, Heroin, Cocaine, and Psychostimulants with Abuse Potential, with (A) and without (B) Synthetic Opioids Other Than Methadone—United States, 2013–2019. National Vital Statistics System, Mortality File, Available online: https://www.cdc.gov/mmwr/volumes/70/wr/mm7006a4.htm?s_cid=mm7006a4_w#F1_down.

5. Trends in indicators of injection drug use, Indian Health Service, 2010–2014: A study of health care encounter data;Evans;Public Health Rep.,2020

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3